文献速递肺外科

新辅助化疗免疫治疗后单孔机器人肺切除术的可行性

Single-Port Robotic Pulmonary Resection for Non-Small-Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy.
PubMed 文献 · Eur J Cardiothorac Surg · 2026-01-01

该回顾性研究比较了新辅助化疗免疫治疗后非小细胞肺癌患者接受单孔机器人或单孔电视辅助胸腔镜肺切除术的围术期结果。结果显示单孔机器人肺切除术技术可行且围术期结果可接受,单孔入路(包括机器人和VATS)可作为合适的NSCLC患者的微创手术选择。

要点

  • 单孔机器人肺切除在新辅助化疗免疫治疗后技术可行且安全。
  • 两组R0切除率分别为90%和93%,中转开胸率分别为10%和29%。
  • 围术期结果如手术时间、淋巴结清扫数、引流液量、住院时间和并发症两组相当。

核心结论

  • 新辅助化疗免疫治疗后单孔机器人肺切除术技术可行,围术期结果可接受。
  • 单孔入路(机器人和VATS)可作为合适的NSCLC患者的微创手术替代方案。

研究设计与样本

  • 回顾性研究,纳入2018年3月至2025年11月在韩国高丽大学九老医院接受新辅助化疗免疫治疗后单孔机器人或单孔VATS肺切除术的患者。

主要发现

  • 基线特征除组织学类型(P = .033)和免疫治疗类型(P = .011)外可比。
  • 单孔VATS组1例(7%)行全肺切除术。
  • R0切除率机器人组90%,VATS组93%(P = 1.000);中转开胸率机器人组10%,VATS组29%(P = .358)。
  • 手术时间、淋巴结清扫数、引流液量、住院时间、术后并发症和术后疼痛等围术期结果两组相当。
  • 单孔VATS组1例死于心肌梗死。

临床怎么用

  • 对于经过适当选择的NSCLC患者,新辅助化疗免疫治疗后可采用单孔机器人或单孔VATS肺切除术。
  • 单孔机器人手术中转开胸率数值上低于VATS(10% vs 29%),但差异无统计学意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the feasibility of single-port (SP) robotic pulmonary resection after neoadjuvant chemoimmunotherapy for non-small-cell lung cancer (NSCLC). METHODS: We retrospectively reviewed data from patients who underwent SP robotic or SP video-assisted thoracic surgery (VATS) pulmonary resection after neoadjuvant chemoimmunotherapy at Korea University Guro Hospital between March 2018 and November 2025 and compared baseline characteristics, intraoperative and perioperative outcomes, and postoperative complications between the 2 groups. RESULTS: Twenty-four patients were included: 10 in the SP robotic group and 14 in the SP VATS group. Baseline characteristics were comparable, except for histologic type (P = .033) and immunotherapy type (P = .011). One pneumonectomy was performed in the SP VATS group (7%). R0 resection rates were 90% in the SP robotic group and 93% in the SP VATS group (P = 1.000). The conversion rate to thoracotomy was 10% in the SP robotic group and 29% in the SP video-assisted group (P = .358). Other perioperative outcomes, including operative time, lymph node yield, drainage volume, hospital stay length, postoperative complications, and postoperative pain, were comparable between groups. One patient in the SP video-assisted group died of myocardial infarction. CONCLUSIONS: Single-port robotic pulmonary resection after neoadjuvant chemoimmunotherapy is technically feasible and can be performed safely with acceptable perioperative results. Our findings suggest that SP approaches, including robotic and VATS techniques, can serve as viable minimally invasive surgical alternatives for appropriately selected patients with NSCLC.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Lee JH, Choi J, Kang EJ, et al. Single-Port Robotic Pulmonary Resection for Non-Small-Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy. Eur J Cardiothorac Surg. 2026. PMID: 42102252. doi:10.1093/ejcts/ezag092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。